The new treatment is being developed by Accelerated Evolution Biotechnologies with scientists believing a cure could be just a year away.
In an interview, AEBi board chairman Dan Aridor sounded optimistic about bringing the drug to market.
The scientists will analyze it and give the patient a personalized cocktail of MuTaTo that will specifically destroy their particular cancer.
That translates to about 2.6 million fewer cancer deaths total than would have been expected if death rates stayed at their peak, which was seen in 1991, according to the study.
The experts even claimed the drug's side effects will be next to nothing, especially when compared to traditional cancer treatments like chemotherapy and radiotherapy.
Morad also said MuTaTo will decrease the side effects of taking anti-cancer drugs "dramatically" because the drug does not target non-cancerous cells.
‘Don’t help elect Trump, a**hole!’ Independent Howard Schultz heckled at bookstore event
Trump responded Monday morning, tweeting, " Howard Schultz doesn't have the "guts" to run for President! ". "I want to see America win".
In contrast, the lab says MuTaTo uses a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill only cancer cells.
"Our solution will be both generic and personal", Aridor stated.
Dr Ilan Morad, a colleague of Aridor, said he was hopeful about the cure.
"It is not really fair for them to announce something like this without really properly vetting it, without peer-reviewed publications or with a clinical trial", said Moffit Cancer Center researcher Vince Luca. "Not even cancer can mutate three receptors at the same time".
"We make sure that the treatment is not affected by the mutations; the cancer cells can mutate in such a way that the cancer discards the targeted receptors".
"However, as experience has taught us so many times, the gap from a successful mouse experiment to effective, beneficial application of exciting laboratory concepts to helping cancer patients at the bedside is in fact a long and treacherous journey, filled with unforeseen and unanticipated obstacles".
AEBi plans to begin clinical trials which could be completed within a few years and would make the treatment available in specific cases.